Bone marrow stem cells in the infarcted heart

Coronary Artery Disease

Volumn 16, Issue 2, 2005, Pages 99-103

  Haider, Husnain Kh ^a   Ashraf, Muhammad ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Bone marrow; Heart; Myocardial infarction; Stem cells; Transplantation

Indexed keywords

CARDIAC MYOSIN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR GATA 4;

CELL DEATH; CELL DIFFERENTIATION; CELL REGENERATION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; ECHOCARDIOGRAPHY; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MESENCHYME; MONONUCLEAR CELL; MYOBLAST; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BONE MARROW; BONE MARROW TRANSPLANTATION; HUMANS; MYOCARDIAL INFARCTION; STEM CELLS; TISSUE ENGINEERING;

EID: 15344338816     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200503000-00004     Document Type: Review

References (34)

1. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7:430-436.
2. Davani S, Marandin A, Mersin N, Royer B, Kantelip B, Herve R et al. Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. Circulation 2003; 108:253-258.
3. Nakauchi H. Hematopoietic stem cells: are they CD34-positive or CD34-negative? Nat Med 1998; 4:1009-1010.
4. Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004; 104: 3581-3587.
5. Matsuura K, Nagai T, Nishigaki N, Oyama T, Nishi J, Wada H, et al. Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J Biol Chem 2004; 279:11384-11391.
6. Stamm C, Westphal B, Kleine H-D, Petzsch M, Kittner C, Klinge H, et al. Autologous BM stem cell transplantation for myocardial regeneration. Lancet 2003; 361:45-46.
7. Lum LG, Fok H, Sievers R, Abedi M, Queensberry PJ, Lee RJ. Targeting Lin-Sca+ heamatopietic stem cells with bi-specific antibodies to injured myocardium. Blood Cells Mol Disease 2004; 32:82-87.
8. Abedi M, Greer DA, Colvin GA, Demers DA, Dooner MS, Harpel JA, et al. Tissue injury in marrow transdifferentiation. Blood Cells Mol Disease 2004; 32:42-46.
9. Fernandez-Aviles F, Alberto San Roman J, Garcia-Frade J, Eugenia Fernandez M, Penarrubia MJ, De La Fuente L, et al. Experimental and clinical regenerative capability of human BM cells after myocardial infarction. Circ Res 2004; 95:742-748.
10. Herzog EL, Chai L, Krause DS. Plasticity of marrow-derived stem cells. Blood 2003; 102:3483-3493.
11. Anderson DJ, Gage FH, Weissman IL. Can stem cell cross lineage boundaries? Nat Med 2001; 7:393-395.
12. Yeh ETH, Zhang S, Wu HD, Korbling M, Willerson JT, Estrov Z. Transdifferentiation of human peripheral blood CD34+ enriched cell population into cardiomyocytes, endothelial cells and smooth muscle cells in vivo. Circulation 2003; 108:2070-2073.
13. Xu W, Zhang X, Qian H, Zhu W, Sun X, Hu J, et al. Mesenchymal stem cells from adult human BM differentiates into a cardiomyocyte phenotype in vitro. Exp Biol Med (Maywood) 2004; 229:623-631.
14. Ying QL, Nichols J, Evans EP, Smith AG. Changing potency by spontaneous fusion. Nature 2002; 416:545-548.
15. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004; 428: 664-668. The results of the study have shown that the transplanted BM cells do not transdifferentiate into cardiomyocytes in vivo after transplantation.
16. Bel A, Messas E, Agbulut O, Richard P, Samuel JL, Bruneval P, et al. Transplantation of autologous fresh BM into infarcted myocardium: a word of caution. Circulation 2003; 108:247-252.
17. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. BM cells regenerate infarcted myocardium. Nature 2001; 410:701-705. The study showed that the locally delivered Lin-ckit+ BM cells can generate de novo myocardium through milieu dependent differentiation of the donor cells.
18. Kehat I, Kenyagin-Karsenti D, Snir M, Segev H, Amit M, Gepstein A, et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001; 108: 407-414.
19. Hakuno D, Fukuda K, Makino S, Konishi F, Tomita Y, Manabe T, et al. BM-derived regenerated cardiomyocytes (CMG Cells) express functional adrenergic and muscarinic receptors. Circulation 2002; 105:380-386.
20. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999; 103:697-705. The study supports the notion that induction of directed transdifferentiation of BM cells is possible by treatment of BM cells with 5aza.
21. Xu M, Wani M, Yan-Shan, Wang J, Yan M, Ayub A et al. Differentiation of BM stromal cells into cardiac phenotype requires intercellular communication with myocytes. Circulation 2004; 110:2658-2665. The study provides significant and much needed evidence that cell-cell interaction between BM cells and the cardiomyocytes is required for their myogenic transdifferentiation.
22. Bittira B, Kuang J-Q, Al-Khaldi A, Shum-Tim D, Chiu R C-J. In vitro pre-programming of marrow stromal cells for myocardial regeneration. Ann Thorac Surg 2002; 74:1154-1160.
23. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103:2776-2779.
24. Kudo M, Wang Y, Wani MA, Xu M, Ayub A, Ashraf M. Implantation of BM stem cells reduces the infarction and fibrosis in ischemic mouse heart. J Mol Cell Cardiol 2003; 35:1113-1119. The study signifies the myogenic potential of the BM derived lin-ckit+ cells and shows that locally transplanted BM cells can reduce the infarct size and fibrosis in ischemically damaged heart muscle.
25. Tse H-F, Kwong Y-L, Chan JKF, Lo G, Ho C-L, Lau C-K. Angiogenesis in ischemic myocardium by intramyocardial autologous BM mononuclear cell implantation. Lancet 2003; 361:47-49.
26. Galinanes M, Loubani M, Davies J, Chin D, Pasi J, Bell PR. Auto-transplantation of un-manipulated BM into scarred myocardium is safe and enhances cardiac function in humans. Cell Transplant 2004; 13:7-13.
27. Chen S-L, Fang W-W, Ye F, Liu Y-H, Qian J, Shan S-J, et al. Effect on left ventricular function of intracoronary transplantation of autologous BM mesenchymal stem cells in patients with acute myocardial infarction. Am J Cardiol 2004; 94:92-95.
28. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomized controlled clinical trial. Lancet 2004; 364:141-148. This study is one of the three phase I studies using BM cell transplantation with largest number of patients. Unlike most other studies, the study also includes a control group of patients without cell transplantation.
29. Perin EC, Dohmann HFR, Borojevic R, Silva SA, Sousa ALS, Mesquita CT, et al. Transendocardial, autologous BM cell transplantation for severe, chronic ischemic heart failure. Circulation 2003; 107: 2294-2302.
30. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002; 106:3009-3017.
31. Minatoguchi S, Takemura G, Chen XH, Wang N, Uno Y, Koda M, et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by post infarction granulocyte colony-stimulating factor treatment. Circulation 2004; 109:2572-2580.
32. Seider C, Pohl T, Wustmann K, Hutter D, Nicolet PA, Windecker S, et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 2001; 104: 2012-2017.
33. Yan X-Q, Briddell R, Hartley C, Stoney G, Samal B, McNiece I. Mobilization of long-term hematopoietic reconstituting cells in mice by the combination of stem cell factor plus granulocyte colony-stimulating factor. Blood 1994; 84:795-799.
34. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Habler L, Ponmaryov T, et al. G-CSF induces stem cell mobilization by decreasing BM SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3:687-694. The study signifies the role of SDF-1/CXCR4 axis to explain the mechanistic basis of BM stem cell mobilization using GCSF.